主页 > 生命科学 >
【medical-news】Gastrin Based Therapies
The gastrin based therapies program is focused on the development of gastrin analogues, alone or in combination with approved or experimental diabetes agents as potential disease modifying therapies for diabetes patients. Preclinical data in diabetes animal models demonstrate the efficacy of gastrin analogues alone, or in combination with GLP-1 analogues or epidermal growth factor analogues. In humans, Transition''s recent Phase IIa clinical trial data showed that 4-weeks of E1-I.N.T. therapy (combination of gastrin analogue, TT-223, and an epidermal growth factor analogue) in type 2 diabetes patients resulted in sustained reductions in blood glucose control parameters, including haemoglobinA1C, for 6 months post-treatment. These data suggest that gastrin based therapies might have an important role in beta cell differentiation and function, capable of providing sustained glucose control in type 2 diabetes. 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 The gastrin based therapies program is focused on the
development of gastrin analogues, alone or in combination with approved or experimental diabetes agents as potential disease modifying therapies for diabetes patients.
目前，用胃泌素的治疗项目集中于胃泌素的类似物的研究进展，这种药物单独或者与已证实或者还未被证实的糖尿病因素一起可以成为治疗糖尿病患者的一种潜在的疗法。
Preclinical data in diabetes animal models demonstrate the efficacy of gastrin analogues alone, or in combination with GLP-1 analogues or epidermal growth factor analogues.
在糖尿病的动物模型的临床前期实验数据表明了胃泌素类似物自己或者和GLP-1类似物或者和表皮生长因子类似物一起的有效性
In humans, Transition''s recent Phase IIa clinical trial data showed that 4-weeks of E1-I.N.T. therapy (combination of gastrin analogue, TT-223, and an epidermal growth factor analogue) in type 2 diabetes patients resulted in sustained reductions in blood glucose control parameters, including haemoglobinA1C, for 6 months post-treatment.
在人类，近期的临床2期试验数据表明经过4周的E1-I.N.T.治疗（胃泌素类似物TT-223和一种表皮生长因子类似物的联合用药）2型糖尿病的病人会导致持续性的血糖控制参数的下降，在接受6个月的后续治疗后，血红蛋白也会下降。
These data suggest that gastrin based therapies might have an important role in beta cell differentiation and function, capable of providing sustained glucose control in type 2 diabetes.
这些数据都表明用胃泌素治疗这种方案可能对于beta细胞的分化和功能还有重要的作用，他可以对2型糖尿病患者提供一个持续性的控制病人的血糖含量。 [标签:content1][标签:content2]
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-01-18 05:14
医学,生命科学网